查找地点
有关时间、上门服务和预约查找地点
有关时间、上门服务和预约7 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
|
7 - 10 days |
Serum
Serum Serum |
Serum Serum |
0.3 mL
0.3 mL 0.3 mL |
0.3 mL 0.3 mL |
0.1 mL (Note: This volume does not allow for repeat testing.)
Gel-barrier tube; red-top tube
Gel-barrier tube; red-top tube Gel-barrier tube; red-top tube |
Gel-barrier tube; red-top tube Gel-barrier tube; red-top tube |
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube.
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube. Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube. |
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube. Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube. |
Refrigerate
Refrigerate Refrigerate |
Refrigerate Refrigerate |
Temperature | Period |
---|---|
Room temperature | 7 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x6 |
|
||||||||||||||||||||
|
Reduced or absent GHBP is found in GH insensitivity due to inactivating receptor binding mutations as typified by Laron dwarfism. The most clinically relevant use of GHBP measurements is to confirm suspected Laron dwarf GH insensitivity due to genetic GH receptor defect. Other forms of GH receptor insensitivity, however may have normal or high GHBP levels. The levels of GHBP may be explained by the underlying mechanism for insensitivity, accordingly, inability to dimerize, errors in the trans-membrane structure, or in downstream actions may have high or normal GHBP levels.
Studies show that GHBP levels decrease in acromegaly, with normalization on successful treatment. The converse is not true – high GHBP levels are not found associated with GH deficiency.
Reduced or absent GHBP is found in GH insensitivity due to inactivating receptor binding mutations as typified by Laron dwarfism. The most clinically relevant use of GHBP measurements is to confirm suspected Laron dwarf GH insensitivity due to genetic GH receptor defect. Other forms of GH receptor insensitivity, however may have normal or high GHBP levels. The levels of GHBP may be explained by the underlying mechanism for insensitivity, accordingly, inability to dimerize, errors in the trans-membrane structure, or in downstream actions may have high or normal GHBP levels. Studies show that GHBP levels decrease in acromegaly, with normalization on successful treatment. The converse is not true – high GHBP levels are not found associated with GH deficiency. Reduced or absent GHBP is found in GH insensitivity due to inactivating receptor binding mutations as typified by Laron dwarfism. The most clinically relevant use of GHBP measurements is to confirm suspected Laron dwarf GH insensitivity due to genetic GH receptor defect. Other forms of GH receptor insensitivity, however may have normal or high GHBP levels. The levels of GHBP may be explained by the underlying mechanism for insensitivity, accordingly, inability to dimerize, errors in the trans-membrane structure, or in downstream actions may have high or normal GHBP levels. Studies show that GHBP levels decrease in acromegaly, with normalization on successful treatment. The converse is not true – high GHBP levels are not found associated with GH deficiency. |
Reduced or absent GHBP is found in GH insensitivity due to inactivating receptor binding mutations as typified by Laron dwarfism. The most clinically relevant use of GHBP measurements is to confirm suspected Laron dwarf GH insensitivity due to genetic GH receptor defect. Other forms of GH receptor insensitivity, however may have normal or high GHBP levels. The levels of GHBP may be explained by the underlying mechanism for insensitivity, accordingly, inability to dimerize, errors in the trans-membrane structure, or in downstream actions may have high or normal GHBP levels. Studies show that GHBP levels decrease in acromegaly, with normalization on successful treatment. The converse is not true – high GHBP levels are not found associated with GH deficiency. Reduced or absent GHBP is found in GH insensitivity due to inactivating receptor binding mutations as typified by Laron dwarfism. The most clinically relevant use of GHBP measurements is to confirm suspected Laron dwarf GH insensitivity due to genetic GH receptor defect. Other forms of GH receptor insensitivity, however may have normal or high GHBP levels. The levels of GHBP may be explained by the underlying mechanism for insensitivity, accordingly, inability to dimerize, errors in the trans-membrane structure, or in downstream actions may have high or normal GHBP levels. Studies show that GHBP levels decrease in acromegaly, with normalization on successful treatment. The converse is not true – high GHBP levels are not found associated with GH deficiency. |
Results of this test are labeled for research purposes only by the assay's manufacturer. The performance characteristics of this assay have not been established by the manufacturer. The result should not be used for treatment or for diagnostic purposes without confirmation of the diagnosis by another medically established diagnostic product or procedure. The performance characteristics were determined by LabCorp.
Results of this test are labeled for research purposes only by the assay's manufacturer. The performance characteristics of this assay have not been established by the manufacturer. The result should not be used for treatment or for diagnostic purposes without confirmation of the diagnosis by another medically established diagnostic product or procedure. The performance characteristics were determined by LabCorp. Results of this test are labeled for research purposes only by the assay's manufacturer. The performance characteristics of this assay have not been established by the manufacturer. The result should not be used for treatment or for diagnostic purposes without confirmation of the diagnosis by another medically established diagnostic product or procedure. The performance characteristics were determined by LabCorp. |
Results of this test are labeled for research purposes only by the assay's manufacturer. The performance characteristics of this assay have not been established by the manufacturer. The result should not be used for treatment or for diagnostic purposes without confirmation of the diagnosis by another medically established diagnostic product or procedure. The performance characteristics were determined by LabCorp. Results of this test are labeled for research purposes only by the assay's manufacturer. The performance characteristics of this assay have not been established by the manufacturer. The result should not be used for treatment or for diagnostic purposes without confirmation of the diagnosis by another medically established diagnostic product or procedure. The performance characteristics were determined by LabCorp. |
Enzyme-linked immunosorbent assay (ELISA)
Enzyme-linked immunosorbent assay (ELISA) Enzyme-linked immunosorbent assay (ELISA) |
Enzyme-linked immunosorbent assay (ELISA) Enzyme-linked immunosorbent assay (ELISA) |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf